Major Depressive Disorder Market: Latest Study by DelveInsight Forecasts Remarkable Growth by 2032 | AbbVie, Arrivo, BioLite, Bristol-Myers Squibb, Gedeon Richter, Janssen, Luye Pharma, Neumora, Novartis, Otsuka, Takeda

DelveInsight's "Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Major Depressive Disorder Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Major Depressive Disorder therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Major Depressive Disorder treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Major Depressive Disorder: An Overview
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. It has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. Major depressive disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.

It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, one of which must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with Major Depressive Disorder.

The treatment strategies for depression consist of both pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy, and transcranial magnetic stimulation. In recent years, psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines increasingly recommend psychotherapy as a monotherapy or in combination with antidepressants.

Major Depressive Disorder Market Key Facts
• The Major Depressive Disorder Market size in the seven major markets was approximately USD 5,600 million in 2021, and it is expected to grow by 2032.
• As per DelveInsight, the Major Depressive Disorder Market is anticipated to evolve immensely in the coming years owing to the launch of new therapies in the market and the rise in the number of cases of Major Depressive Disorder in the 7MM.
• In 2021, the total 12-month prevalent cases of Major Depressive Disorder in the 7MM exceeded 48 million, out of which the highest 12-month prevalent cases were observed in the United States. The EU5 countries accounted for more than 20 million cases as a whole in 2021.
• In 2021, there were about 4.8 million Refractory (or TRD) cases of Major Depressive Disorder in the United States. The overall refractory cases of Major Depressive Disorder in the US are subject to increase in the coming years.

Get a Detailed Overview of the Evolving Major Depressive Disorder Market Trends @
https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Depressive Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Major Depressive Disorder therapies in the market. It also provides a detailed assessment of the Major Depressive Disorder market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Major Depressive Disorder drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Major Depressive Disorder Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Depressive Disorder Epidemiology
The epidemiology section covers detailed insights into the historical, and current Major Depressive Disorder patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Major Depressive Disorder Epidemiology Segmented as -
• 12 Months Prevalent Cases of Major Depressive Disorder in the 7MM [2019-2032]
• Severity-specific Cases of Major Depressive Disorder in the 7MM [2019-2032]
• Gender-specific Prevalence of Major Depressive Disorder in the 7MM [2019-2032]
• Refractory (or TRD) Cases of Major Depressive Disorder in the 7MM [2019-2032]

Get Key Insights Into the Evolving Major Depressive Disorder Epidemiology Trends @
https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Depressive Disorder Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Major Depressive Disorder market or expected to be launched during the study period. The analysis covers the market share by Major Depressive Disorder drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Major Depressive Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Major Depressive Disorder Market @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Depressive Disorder Therapeutics Assessment
Selective serotonin inhibitors (SSRI), Serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, and tricyclic antidepressants are currently approved classes of therapies for treating Major Depressive Disorder. In the past few decades, most antidepressant discoveries focused on finding faster, safer, and more selective serotonin or norepinephrine receptor targets. In addition, there is an urgent need to develop new approaches to obtain more effective, safer, and faster antidepressants. Several drugs have been approved for Major Depressive Disorder by regulatory authorities including TRINTELLIX, FETZIMA, and REXULTI, among others.

Recently, the US FDA approved AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of Major Depressive Disorder in adults in August 2022 and VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder in December 2022.

To improve the treatment scenario, several major pharma and biotech companies are developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics is leading the therapeutics market with its Major Depressive Disorder drug candidates in the most advanced stage of clinical development.

Leading Companies in the Major Depressive Disorder Therapeutics Market Include
AbbVie, Alto Neuroscience, Arrivo Bioventures, Axsome Therapeutics, BioLite Inc., BlackThorn Therapeutics, Inc., Bristol-Myers Squibb, Chase Therapeutics, Fabre-Kramer Pharmaceuticals, Forest Laboratories, Gedeon Richter, GH Research, Intra-Cellular Therapies, Janssen Research & Development, Luye Pharma, Minerva Neurosciences, Neumora Therapeutics, Inc., Neurocrine Biosciences, Novartis, Otsuka Pharmaceutical Co., Ltd., Pherin Pharmaceuticals, Praxis Precision Medicines, Relmada Therapeutics, SAGE Therapeutics, Sirstei Pharmaceuticals, Takeda, Takeda Pharmaceuticals, VistaGen Therapeutics, and others.

Emerging and Marketed Major Depressive Disorder Therapies Covered in the Report Include
ABV-1504: BioLite Inc., ALTO-300: Alto Neuroscience, AXS-05: Axsome Therapeutics, Brintellix: Takeda Pharmaceuticals, CAPLYTA (Lumateperone): Intra-Cellular Therapies, CTC-501: Chase Therapeutics, Fetzima: Forest Laboratories, LY03005: Luye Pharma, MIJ821: Novartis, MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences, NBI-1065845: Neurocrine Biosciences, NMRA-140: Neumora Therapeutics, Inc./BlackThorn Therapeutics, Inc., OPC-64005: Otsuka Pharmaceutical Co., Ltd., PDC-1421: BioLite Inc, PRAX-114: Praxis Precision Medicines, REL-1017: Relmada Therapeutics, Rexulti: Otsuka Pharmaceuticals, SAGE-217: Sage Therapeutics, Seltorexant: Minerva Sciences, SP-624: Arrivo Bioventures/Sirstei Pharmaceuticals, SPL026: Small Pharma, SPRAVATO (Esketamine): Janssen Research & Development, Travivo: Fabre-Kramer Pharmaceuticals, Vraylar (Cariprazine): AbbVie, Zuranolone (SAGE-217/BIIB125): SAGE Therapeutics, and many more.

Learn More About the Emerging Therapies and key Companies in the Major Depressive Disorder Therapeutics Market @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Latest Clinical, Commercial, and Regulatory Developments in the Major Depressive Disorder Therapeutics Market
• On 5 June 2023, ANeuroTech announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a pivotal Phase IIIB trial of ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder. Phase IIIB will include secondary endpoints of improvements in cognitive function and the ability to feel pleasure, the first time these have been included in an anti-depression drug clinical trial. ANeuroTech expects to begin the trial later this year.
• On Feb. 06, 2023, Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of the Major Depressive Disorder and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD.
• On December 06, 2022, Vistagen (NASDAQ: VTGN) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of PH10, one of the Company's investigational nasal sprays, for the treatment of the Major Depressive Disorder.

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Major Depressive Disorder Competitive Intelligence Analysis
4. Major Depressive Disorder Market Overview at a Glance
5. Major Depressive Disorder Background and Overview
6. Major Depressive Disorder Patient Journey
7. Major Depressive Disorder Epidemiology and Patient Population
8. Major Depressive Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Major Depressive Disorder Unmet Needs
10. Key Endpoints of Major Depressive Disorder Treatment
11. Major Depressive Disorder Marketed Products
12. Major Depressive Disorder Emerging Therapies
13. Major Depressive Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Major Depressive Disorder Market Outlook (7 major markets)
16. Major Depressive Disorder Access and Reimbursement Overview
17. KOL Views on the Major Depressive Disorder Market.
18. Major Depressive Disorder Market Drivers
19. Major Depressive Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.